Literature DB >> 6247768

"Prespondylosis" and some pain syndromes following denervation supersensitivity.

C C Gunn.   

Abstract

Pain is determined by the neurologic properties of receptor organs, neurons, and their interconnections. These may become supersensitive or hyperreactive following denervation (Cannon's Law). A common cause of denervation in the peripheral nervous system is neuropathy or radiculopathy as a sequel to spondylosis. Spondylosis in its early stage may be "asymptomatic" or painless and hency unsuspected, because small-diameter pain fibers may not initially be involved despite the attenuation of the other component fibers of the nerve. The term "prespondylosis" is introduced here to describe this presently unrecognized phase of insidious attrition to the other functions of the nerve, especially the trophic aspect. It is postulated that many diverse pain syndromes of apparently unrelated causation may be attributed to abnormal noxious input into the central nervous system from supersensitive receptor organs (nociceptors) and hyperreactive control systems at internuncial pools. Furthermore, trauma to a healthy nerve is usually painless or only briefly painful, unless there is preexisting neuropathy. Some pain syndromes in muscle (eg, trigger points and myofascial pain syndromes) and nerve (eg, causalgia and diabetic neuropathy) that may be related to denervation are discussed.

Entities:  

Mesh:

Year:  1980        PMID: 6247768     DOI: 10.1097/00007632-198003000-00014

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  2 in total

1.  Case report: Myofascial pain syndrome: a double crush-like appearance.

Authors:  R Kevin Pringle; Daniel L Richardson; Robert S Shiel
Journal:  J Chiropr Med       Date:  2003

2.  The effect of Gunn's intramuscular stimulation for postherpetic neuralgia -A report of 4 cases-.

Authors:  Wook Jung; Byung-Jun Lee; Sin Sung Kim; Young Jin Lee
Journal:  Korean J Anesthesiol       Date:  2010-03-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.